Celldex Therapeutics, Inc. (CLDX)

Import this data to Google Sheets with:

=jivedata("CLDX","financials")

Full statements spill as a table. For one cell: =jivedata("CLDX","Revenue") or =jivedata("CLDX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Celldex Therapeutics, Inc.

CLDX • CIK 0000744218

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-154,542	$-195,078	$-287,367	$-325,828
Interest and Other Income	$13,113	$37,215	$28,610	$25,279
Net Income (Loss) Attributable to Parent	—	—	$-258,757	$-300,549
Weighted Average Number of Shares Outstanding, Basic	48,449	64,395	66,422,000	138,589,612
Revenue from Contract with Customer, Excluding Assessed Tax	$6,883	$7,020	$1,545	$158
Research and Development Expense	$118,011	$163,550	$245,074	$278,807
General and Administrative Expense	$30,914	$38,548	$43,838	$47,179
Gain (Loss) Related to Litigation Settlement	$-12,500	$-12,500	$-12,500	$-12,500
Costs and Expenses	$161,425	$202,098	$288,912	$325,986
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-139,381	$-157,857	$-258,445	$-302,590
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	$2,048	$6	$312	$-2,041

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$34,814	$28,356	$28,871	$47,454
Marketable Securities, Current	$388,784	$696,925	$489,702	$670,133
Property, Plant and Equipment, Net	$4,060	$4,346	$5,334	$9,756
Accounts and Other Receivables, Net, Current	$2,628	$700	$2,015	$230
Operating Lease, Right-of-Use Asset	$2,577	$3,898	$2,437	$5,038
Prepaid Expense and Other Assets, Current	$5,467	$21,178	$14,076	$7,114
Intangible Assets, Net (Excluding Goodwill)	$27,190	$27,190	$27,190	$27,190
Assets, Current	$431,693	$747,159	$534,664	$724,931
Other Assets, Noncurrent	$107	$9,747	$13,358	$15,434
Assets	$465,627	$792,340	$582,983	$782,349
Operating Lease, Liability, Noncurrent	$928	$2,361	$784	$3,347
Other Liabilities, Noncurrent	$4,403	$3,473	$4,043	$3,113
Liabilities	$36,456	$45,335	$55,818	$67,785
Accounts Payable, Current	$3,494	$3,265	$1,180	$14,675
Accrued Liabilities, Current	$22,029	$33,842	$47,029	$43,863
Operating Lease, Liability, Current	$1,614	$1,452	$1,552	$1,557
Other Liabilities, Current	$3,988	$942	$1,230	$1,230
Liabilities, Current	$31,125	$39,501	$50,991	$61,325
Common Stock, Value, Issued	$56	$66	$67	$79
Additional Paid in Capital, Common Stock	$1,823,168	$2,298,849	$2,337,453	$2,679,356
Accumulated Other Comprehensive Income (Loss), Net of Tax	$3,308	$3,314	$3,626	$1,298
Retained Earnings (Accumulated Deficit)	$-1,397,361	$-1,555,224	$-1,813,981	$-1,966,169
Stockholders' Equity Attributable to Parent	$429,171	$747,005	$527,165	$714,564
Preferred Stock, Shares Authorized	3,000,000	3,000,000	3,000,000	3,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	297,000,000	297,000,000	297,000,000	297,000,000
Common Stock, Shares, Issued	55,883,377	66,374,549	66,549,442	78,500,173

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Available to Common Stockholders, Basic	$-141,429	$-157,863	$-258,757	$-300,549
Net Cash Provided by (Used in) Operating Activities	$-107,291	$-157,778	$-210,945	$-235,566
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$5,385	$-6,458	$515	$24,410
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$34,814	$28,356	$28,871	$47,464
Depreciation, Depletion and Amortization	$3,008	$3,177	$3,380	$3,396
Proceeds from Sale and Maturity of Marketable Securities	$320,597	$501,714	$596,288	$512,291
Accretion (Amortization) of Discounts and Premiums, Investments	$6,222	$15,749	$5,855	$4,228
Payments to Acquire Marketable Securities	$424,561	$789,924	$384,502	$572,883
Gain (Loss) on Disposition of Property Plant Equipment	$-2	$-16	$-12	$-10
Payments to Acquire Property, Plant, and Equipment	$1,818	$1,919	$2,714	$6,539
Share-based Payment Arrangement, Noncash Expense	$23,890	$34,242	$36,217	$34,641
Net Cash Provided by (Used in) Investing Activities	$-105,782	$-290,129	$209,072	$-67,131
Proceeds from Issuance of Common Stock	$216,222	$432,298	$432,298	—
Proceeds from Stock Plans	$2,236	$9,151	$2,388	$3,275
Net Cash Provided by (Used in) Financing Activities	$218,458	$441,449	$2,388	$327,107
Construction in Progress Expenditures Incurred but Not yet Paid	$77	$27	$98	$626
Increase (Decrease) in Accounts and Other Receivables	$2,281	$-1,928	$1,315	$140
Increase (Decrease) in Prepaid Expense and Other Assets	$-5,900	$19,887	$-8,706	$-10,802
Increase (Decrease) in Other Operating Assets	$3	$9,640	$3,611	$6,134
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$9,384	$11,634	$11,031	$27,513
Increase (Decrease) in Other Operating Liabilities	$462	$-5,636	$-753	$-877

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("CLDX","financials")

Full statements spill as a table. For one cell: =jivedata("CLDX","Revenue") or =jivedata("CLDX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.